Researchers found that users of the Dexcom G7 device saw a nearly 1% greater reduction in hemoglobin A1c levels compared to patients receiving routine care. These findings suggest the benefits of wearable monitoring technology extend beyond those currently recommended for insulin therapy. While these devices are currently only recommended for patients who receive insulin, this study demonstrates potential for a broader application.
The study monitored 283 adults with type 2 diabetes who were not on insulin. Participants were divided into two groups: one received routine care, while the other utilized the Dexcom G7, a coin-sized plastic sensor worn on the upper arm. The group using the CGM device saw their average hemoglobin A1c—a measure of blood sugar levels over time—drop from 8.8% to 7.2%. In contrast, the routine care group saw a smaller decrease, moving from 8.7% to 8%. The six-month trial was sponsored by Dexcom, the manufacturer of the devices.
Improvements in Glucose Time-in-Range
Beyond A1c levels, the CGM users maintained blood sugar levels within the target range of 70 to 180 mg/dL for approximately five hours longer per day than those in the routine care group. This benefit remained consistent regardless of variables such as age, gender, race, body mass index, income, education level, health insurance status, or the specific glucose-lowering medications prescribed. Researchers noted that 97% of participants continued to use the sensors, and most did so daily, by the conclusion of the six-month trial.
Routine and Circadian Rhythms in Diabetes Care
While the Dexcom study focused on sensor technology, other research highlights the role of lifestyle consistency. In that study of 122 patients with type 2 diabetes who receive insulin treatment, 46.3% of those with regular circadian rhythms reached their target blood sugar levels, compared to 20% of those with less regular routines. Researchers observed that physical activity between 12:00 p.m. and 6:00 p.m. showed the strongest link to improved glucose control. The researchers also noted that sufficient sleep was associated with greater stability in glucose levels and a reduced risk of hypoglycemic episodes.
Frequently Asked Questions
Are CGM devices currently recommended for all type 2 diabetes patients?
No. These devices are currently only recommended for patients who receive insulin. The recent study aims to provide evidence for expanding that recommendation to patients at earlier stages of the disease.
Did the Dexcom study account for different demographics?
Yes. The researchers confirmed that the benefits of the Dexcom G7 were observed regardless of factors such as age, gender, race, body mass index, income, education level, health insurance status, or the use of glucose-lowering medications.
Can lifestyle modifications aid diabetes management alongside traditional treatment?
Researchers believe that adhering to regular sleep schedules and consistent physical activity may serve as a useful addition to traditional diabetes therapies, as exercise influences hormonal processes and insulin function.
Related reading